# US 11,992,468 B2 · Abuse-deterrent dosage forms containing esketamine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,992,468 B2
- Document ID: US11992468B2
- Status: Granted
- Kind: B2
- Application number: 18/184,270
- Filed: 2023-03-15
- Published: 2023-09-28
- Granted: 2024-05-28
- Earliest claimed: 2019-05-07
- Assignees: Clexio Biosciences Ltd.
- Applicants: Clexio Biosciences Ltd.
- Inventors: Derek Moe; Randal Seburg; Sagar Rane
- Web page: https://patentgrep.com/patent/US11992468B2

## CPC

- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2081: {with microcapsules or coated microparticles according to A61K9/50}
- A61K 9/2095: {Tabletting processes}
- A61P 25/00: Drugs for disorders of the nervous system
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5078: {with drug-free core}
- G01N 2030/027: {Liquid chromatography}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.

## Claims

### Claim 1

A method of manufacturing an immediate release tablet determined to have no more than about 5 wt. % of 2-(2-chlorophenyl)-2-(methylamino)-6-methylidenecyclohexan-1-one comprising
preparing an immediate release tablet comprising between 20 mg and 100 mg of esketamine;
exposing the tablet to a storage period of six months;
after the storage period, measuring by HPLC for the area under a peak corresponding to 2-(2-chlorophenyl)-2-(methylamino)-6-methylidenecyclohexan-1-one present in the tablet; and,
determining by HPLC that the total amount of 2-(2-chlorophenyl)-2-(methylamino)-6-methylidenecyclohexan-1-one present in the tablet is no more than about 5 wt %;
wherein the peak corresponding to 2-(2-chlorophenyl)-2-(methylamino)-6-methylidenecyclohexan-1-one appears at a relative retention time of about 1.3 minutes when using a C18, 100×3.0 mm, 3.51 μm HPLC column at a temperature of 45° C. and a sample temperature of 4° C., with a mobile phase comprising 0.050% TFA in water and 0.0025% TFA in acetonitrile and UV detection rate of 215 nm.

### Claim 2 (depends on 1)

The method of claim 1, wherein the tablet is exposed to 40° C.±2° C. and 75%±5% relative humidity for the six month storage period.

### Claim 3 (depends on 1)

The method of claim 1, wherein the tablet comprises 40-60 mg of esketamine.

### Claim 4 (depends on 1)

The method of claim 1, wherein the tablet comprises 60 mg of esketamine.

### Claim 5 (depends on 1)

The method of claim 1, wherein the tablet further comprises a pH adjuster.

### Claim 6 (depends on 5)

The method of claim 5, wherein the tablet comprises 2 wt %, based on the weight of the tablet, of the pH adjuster.

### Claim 7 (depends on 1)

The method of claim 1, wherein the 2-(2-chlorophenyl)-2-(methylamino)-6-methylidenecyclohexan-1-one is measured in an amount of no more than 0.2 wt % after the storage period.

### Claim 8 (depends on 1)

The method of claim 1, wherein the 2-(2-chlorophenyl)-2-(methylamino)-6-methylidenecyclohexan-1-one is measured in a non-detectable amount after the storage period.